Burjeel mammography truck will visit dozens of Abu Dhabi sites in October

Burjeel Cancer Institute has launched a mobile mammography truck that will visit dozens of locations across Abu Dhabi during Breast Cancer Awareness Month, taking early breast cancer screening into workplaces, schools, malls and residential communities.

The highest-stakes readers are COOs at women’s health and radiology clinics, payer teams managing preventive benefits, and medical directors responsible for referral pathways. The campaign is based in Abu Dhabi, where the Department of Health – Abu Dhabi (DOH) and Abu Dhabi Public Health Centre (ADPHC) support breast screening programmes. Dubai operators should read it against Dubai Health Authority (DHA) guidance, while providers in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain fall under the Ministry of Health and Prevention (MOHAP).

What Burjeel is taking to the market

The Emirates News Agency reported on 30 September 2026 that the truck will cover Abu Dhabi City, Al Ain and surrounding areas. Named stops include Daman, Emirates National Schools, EDGE, Silal, Burjeel Medical Centres in Al Falah and Saadiyat, LLH Hospital in Musaffah, ADNOC in Al Ain, Etihad Airways offices in Abu Dhabi and Al Ain, Zayed Port, Khalifa Port and KEZAD.

Public locations include Umm Al Emarat Park, Deerfields Mall, Ghantoot Racing & Polo Club, Al Forsan International Sports Resort and municipal community facilities in Abu Dhabi City. WAM said screenings will be supervised by a specialised medical and technical team. The truck is positioned as a private screening environment for women who may delay hospital-based appointments.

“Through the Mobile Mammography Truck, we aim to bring screening services closer to women.” Prof. Humaid Al Shamsi, Chief Executive Officer, Burjeel Cancer Institute

The timing matters. On 21 September 2026, WAM reported that DOH had designated Burjeel Cancer Institute at Burjeel Medical City, Cleveland Clinic Abu Dhabi and SEHA Tawam Hospital as Oncology Centres of Excellence for Breast Cancer. DOH also reported an 85% increase in early screening rates in Abu Dhabi over the past year.

What clinics and payers should check

For clinics, the operational issue is follow-up capacity. Mobile screening can create downstream demand for diagnostic mammography, breast ultrasound, biopsy, breast surgery and oncology consultation. A provider that joins a workplace campaign without a recall pathway risks losing the patient after the first abnormal finding.

• Eligibility: DHA’s Periodic Health Screening Guideline, effective 11 May 2024, advises mammography every 2 years for females aged 40 years and over.
• Risk cases: DOH’s breast screening standard includes annual mammography for defined higher-risk groups, including women with a 5-year invasive breast cancer risk of 1.7% or more under the Gail model.
• Cash pricing: Mediclinic publishes AED 375 for a mammogram, AED 350 for breast ultrasound and AED 725 for both, including physician consultation.
• Reporting: Mediclinic tells patients results are shared within 15 working days; operators should publish their own turnaround time before campaign demand arrives.

Insurers should treat the campaign as a utilisation signal. A workplace stop at Daman does not mean every payer covers every screening scenario. Benefits teams should check whether a screening mammogram is covered as preventive care, whether a referral is required, and whether tomosynthesis, ultrasound or biopsy moves the claim into diagnostic coverage.

Why patients may move differently

For patients, the value is convenience and privacy. A 30-minute visit inside a workplace or community site removes transport and scheduling barriers. The follow-up burden remains. A normal result leads back to routine screening intervals. An abnormal result can trigger additional mammographic views, ultrasound, fine needle aspiration, image-guided biopsy or referral to a breast surgeon.

Dubai providers should watch whether Abu Dhabi-style mobile screening changes patient expectations during October. DHA-regulated clinics already compete on women’s health packages, cash prices and insurer access. Northern Emirates providers regulated by MOHAP face the same question with fewer large private oncology hubs in some catchments.

The next test is conversion. Burjeel’s truck may raise screening volume, but the commercial and clinical impact will show in completed recalls, confirmed diagnoses, payer authorisations and treatment starts. Clinics that want to compete should publish eligibility, price, accepted insurers, result turnaround and escalation pathways in one place.

For licensed oncology and breast care options, readers can use the UAE Open Healthcare Directory to compare DHA, DOH and MOHAP-licensed providers across the UAE.